GLOBAL VACCINE TRIALS OF COVID-19
                     GLOBAL VACCINE TRIALS OF 
COVID 19
CANDIDATE 1:Inactivated Vaccine
• Status: Phase 3
• Sponsor: Wuhan Institute of Biological Products 
• Background: Researchers at Sinopharm and the 
Wuhan Institute of Virology under the Chinese 
Academy of Sciences are developing an inactivated 
COVID-19 vaccine candidate. 
• Outcomes: The vaccine has shown a "strong 
neutralizing antibody response" in Phase 1/2 trials.
Source: Times of India
CANDIDATE 2: Corona Vac
• Status: Phase 3
• Sponsor: Sinovac
• Background: CoronaVac is a formalin-inactivated and 
alum-adjuvanted candidate vaccine. 
• Outcomes: Results from the Phase 1/2 trials showed 
no serious adverse events
Source: The Conversation
CANDIDATE 3: Bacillus Calmette-Guerin 
(BCG) live-attenuated vaccine
• Status: Phase 3
• Sponsor: university of Melbourne and Murdoch 
Children’s Research Institute
• Background: The BCG vaccine is indicated to 
prevent tuberculosis in those who have a higher 
risk of the disease.
• Outcomes: BCG vaccines are being studied in the 
randomized, Phase 3 BRACE trial, which aims to 
recruit 4,170 healthcare workers in hospitals in 
Australia. Source: Times of India
CANDIDATE 4: AZD1222
• Status: Phase 3
• Sponsor: The University of Oxford; AstraZeneca; 
IQVIA
• Background:  The Oxford Vaccine Group at the 
University of Oxford are developing a new vaccine 
candidate for COVID-19, a chimpanzee adenovirus 
vaccine vector called AZD1222 (previously 
ChAdOx1).
• Outcomes: Preliminary results from the trial showed 
the vaccine candidate had an “acceptable safety Source: Biospectrum
profile” with most patients demonstrating an 
antibody response.
CANDIDATE 5: mRNA-1273
• Status: Phase 2
• Sponsor: Moderna
• Background: mRNA-1273 was developed by 
Moderna based on severe acute respiratory 
syndrome (SARS) and Middle East respiratory 
syndrome (MERS).
• Outcomes: As per the data published mRNA-1273 
has successfully produced neutralizing antibody 
titers.
Source: The Indian Express
CANDIDATE 6: Ad5-nCoV
• Status: Phase 2
• Sponsor: Cansino Biologics
• Background: China’s CanSino Biologics has 
developed a recombinant novel coronavirus vaccine 
that incorporates the adenovirus type 5 vector 
(Ad5).
• Outcomes: Results from Phase 1 of the trial show a 
humoral and immunogenic response to the vaccine.
Source: Times of India
CANDIDATE 7: Adjuvant recombinant 
vaccine candidate
• Status: Phase 2
• Sponsor: Anhui Zhifei Longcom Biopharmaceutical, 
Institute of Microbiology of the Chinese Academy of 
Sciences
• Background: China's National Medical Products 
Administration has approved a Phase 1 trial of a 
COVID-19 vaccine candidate.
• Outcomes: A Phase 2 trial is underway, with results 
from Phase 1 expected in September.
Source: Daily Graphic
CANDIDATE 8: BNT162
• Status: Phase 1/2
• Sponsor: Pfizer
• Background: Pfizer and BioNtech 
are collaborating on four vaccine candidates 
originally developed by BioNTech.
• Outcomes: Pfizer and BioNtech have  suggests one 
of the BNT162 candidates, BNT162b1, produced a 
neutralizing antibody response in participants 
Source: World Economic Forum
CANDIDATE 9: Covaxin
• Status: Phase 1
• Sponsor: Bharat Biotech
• Background: Bharat Biotech, an Indian 
biotechnology company, is partnering with the 
National Institute of Virology to develop an 
inactivated vaccine candidate for COVID-19 called 
Covaxin. 
• Outcomes: A Phase 1/2 trial of about 1,100 healthy 
participants is underway after approval by the Drug 
Controller General of India. 
Source: Business Standard
CANDIDATE 9: LUNAR-COV19
• Status: Phase 1
• Sponsor: Arcturus and Duke-NUS 
• Background: Arcturus and Duke-NUS Singapore are 
partnering to develop a COVID-19 vaccine candidate 
that uses Arcturus’ self-replicating RNA and 
nanoparticle non-viral delivery system. 
• Outcomes: Arcturus said a Phase 1/2 clinical trials 
will proceed in Singapore.
Source: Times of India
Thank You!!!
Source: India Today Group/ DIU